## GLUCAGON-LIKE PEPTIDE 1 (GLP-1) DRUGS FOR NON-DIABETES INDICATIONS



**Included Products: Wegovy (semaglutide)** 

 Created:
 Revised:
 Reviewed:
 Updated:

 07/11/2024
 07/11/2024
 07/11/2024
 07/11/2024

| Chronic Weight Management-Pediatrics |   |                       |   |  |  |  |
|--------------------------------------|---|-----------------------|---|--|--|--|
| Init                                 | tial Criteria: All Diagnoses  | If yes                | If no   |  |  |  |
| 1.                                   | Is the member between 12 and 20 years of age?   | Continue to #2.       | Deny for Guideline Note. Medications for purposes of weight loss not covered in adults. |  |  |  |
| 2.                                   | Does the member have severe obesity defined as one of the following:  a. Body Mass Index (BMI) of greater than or equal to 35kg/m2; or  b. Equal to or greater than 120% of the 95th percentile for age and sex   | Continue to #3.       | Do not approve.   |  |  |  |
| 3.                                   | Has the member failed Qsymia?   | Continue to #4.       | Do not approve.   |  |  |  |
| 4.                                   | Is there documentation that all of the following have been maximized and failed:  a. Motivational Interviewing b. Health Behavior and Lifestyle Interventions including face-to-face, family based counseling on nutrition and physical activity delivering 26 or more hours over a 3 to 12 month period.  c. Physical activity goals such as daily exercise or reduction in sedentary behavior.  d. Nutrition education/modifications such as reduction of sugar-sweetened beverages and | Approve for 6 months. | Review with a medical director for an assessment of medical necessity/appropriateness.  |  |  |  |

|                  | improvements in health eating.           |             |                 |
|------------------|--|-------------|-----------------|
| Renewal Criteria |  | If yes      | If no           |
| 1.               | Is there documentation of weight loss of | Continue to | Do not approve. |
|                  | at least 5% of baseline BMI?             | #2.         |                 |
| 2.               | Approve for 12 months.                   |             |                 |

## Prevention of secondary cardiovascular events in overweight and obesity

|                   | onto in ovorworghic and ob  | 0011            |  |
|-------------------|---|-----------------|--|
| Initial Criteria: |   | If yes          | If no  |
| 1.                | Is the request for the indication of reducing the risk of major cardiovascular events in an adult with established cardiovascular disease and either obesity or overweight?   | Continue to #2. | Do not approve. Medications for purposes of weight loss not covered in adults. |
| 2.                | Has the member been screen for diabetes in the past 12 months and results show the member does not have diabetes (such as A1c <6.5% or fasting blood glucose <126 mg/dL)?   | Continue to #3. | Do not approve.  |
| 3.                | Is the member 45 years of age or older?   | Continue to #4. | Do not approve.  |
| 4.                | Does the member have a BMI of 27 kg/m <sup>2</sup> or greater?  | Continue to #5. | Do not approve.  |
| 5.                | Does the member have established cardiovascular disease by at least one of the following?  a. History of myocardial infarction: Defined as documentation of myocardial necrosis (such as changes in cardiac biomarkers) and supporting evidence from clinical presentation, electrocardiographic changes or coronary artery imaging.  b. History of stroke (ischemic or hemorrhagic) with confirmation of stroke by imaging.  c. Symptomatic peripheral arterial disease with evidence of one of the following: intermittent claudication with anklebrachial index (ABI) < 0.85 (at rest), or | Continue to #6. | Do not approve.  |

| 6.<br>7. | peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease.  Has the member tried a weight loss treatment plan administered by a health care provider (such as a diet and exercise program, nutritional counseling, or a calorie restricted diet) for at least a 3-month period within the past 6 months?  Is the member prescribed and taking other | Continue to #7.    | Do not approve.                           |
|----------|---|--------------------|---|
|          | recommended drugs for secondary cardiovascular prevention, such as a high intensity statin (such as atorvastatin 40-80 mg or rosuvastatin 20-40 mg) and/or antiplatelet therapy (aspirin or clopidogrel) OR is there a reason these are medically inappropriate for the member?   | #8.                | adding if appropriate and continue to #8. |
| 8.       | Approve for 6 months  |                    |   |
| Rer      | newal Criteria  | If yes             | If no                                     |
| 1.       | Has the member lost or maintained a BMI reduction of 5% or more?  | Continue to #3.    | Do not approve.                           |
| 2.       | Is the member continuing with a weight loss treatment plan (diet and exercise program, nutritional counseling, or calorie restricted diet)?   | Continue to<br>#4. | Do not approve.                           |
| 3.       | Approve for 12 months.  |                    |   |